Decibel Therapeutics submits IND application for hearing loss gene therapy candidate
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
List view / Grid view
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
The best protection from COVID-19 will come from intranasally-delivered vaccines, due to the effectiveness of mucosal IgA antibodies, say researchers from the University at Buffalo.
A newly developed AAV has shown promise at delivering gene therapies to the brain in mice and non-human primates.
Researchers in the US have developed a potential HIV vaccine approach that aims to prompt the creation of broadly neutralising antibodies via mRNA.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.
The researchers found that augmenting NPHP5 gene rescues cilia defects in light-sensing cells derived from ciliopathy patients.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.